Jordan Berlin was named interim leader of the Division of Hematology and Oncology in the Department of Medicine at Vanderbilt University Medical Center.
A $10 million gift from the Brock family, including John F. Brock III, his wife, Mary, and their three adult children—Rebecca Brock Dixon, John F. Brock IV and Major Brock—will establish the Brock Family Center for Applied Innovation at Vanderbilt University Medical Center.
OneOncology has formed five OneOncology disease groups.
Sarah Quinlan was named chief program officer of The Lymphoma Research Foundation.
Researchers who developed a camera technology inspired by the mantis shrimp’s visual system have received a $9 million P01 award from NCI.
University Hospitals Cleveland Medical Center was designated as the first SpaceOAR Hydrogel Center of Excellence in the world, led by urologic oncologist Jonathan Shoag, and radiation oncologist Daniel Spratt.
In a study published in JAMA Network Open, researchers at Yale Cancer Center assessed the acceptance of Medicaid insurance among patients diagnosed with common cancers.
Merck plans to stop the phase III LYNK-003 trial investigating Lynparza with or without bevacizumab for the treatment of patients with unresectable or metastatic colorectal cancer who have not progressed following first-line induction, citing futility.
Scientists from the International Agency for Research on Cancer, Barretos Cancer Hospital (Brazil), and partners have identified multi-omics markers of exposure to ultraviolet radiation that are critically involved in immune function, have the potential to drive cancer development, and could be used to predict the survival of patients with cutaneous melanoma, which occurs mainly in fair-skinned people.
FDA has granted Fast Track designation for the development program of eltanexor as monotherapy for the treatment of patients with relapsed or refractory intermediate, high-, or very high-risk myelodysplastic syndromes (MDS).
